Amid Expected Enhertu Entry, Chinese Domestic ADC Developers Race To Market

'Fast-Follower' Strategy?

 
• By Dexter Jie Yan

12 biotechs in China are preparing to compete for domestic market share for their home-grown HER2-targeted antibody-drug conjugates amid Enhertu’s in-roads in the country.

Chinese developers are flocking to ADC drugs after seeing chances of blockbuster success.
At least 12 HER2-targeted ADCs in clinical studies in China • Source: Alamy

More from China

More from Focus On Asia